前立腺肥大症のホルモン療法 とくに,SH-582(19-nor-17α-hydroxy-progesterone capronate)の臨床効果について

Abstract

In recent years, therapeutic success with progestogens in prostatic hypertrophy has been reported, but the effects of progestogens on the prostate are still unestablished. In our animal experiments, the progestogen was demonstrated to have more or less anti-androgenic activities when its effects on the prostatic growth promoted by testosterone were examined. The progestogen appears probably to act directly upon the prostatic glandular tissues with its antiandrogenic effects, since the atrophy of glandular epithelia was observed in the hypertrophied prostatic tissue extracted following the treatment. Clinical improvements of subjective symptoms, urethrograms and residual urine were obtained in about half the cases treated with the progestogen over a certain period.